Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03991884
• Other study ID #: RG1004854
• Secondary ID: NCI-2019-0381187
• Status: Completed
• Phase: Phase 1
• Start date: September 24, 2019
• Est. completion date: June 28, 2023

Study information

• Verified date: June 2023
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the best dose of inotuzumab ozogamicin in combination with chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin in combination with chemotherapy may kill more cancer cells than with chemotherapy alone in treating patients with recurrent or refractory B-cell acute lymphoblastic leukemia.

Description:

This is a dose-escalation study of inotuzumab ozogamicin.

Patients receive etoposide, doxorubicin, and vincristine intravenously (IV) via continuous infusion on days 1-4, prednisone orally (PO) or IV twice daily (BID) on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days then annually for up to 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 28, 2023
• Est. primary completion date: October 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have a confirmed diagnosis of CD22-positive, Philadelphia chromosome (Ph)-positive or Ph-negative B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. CD22 expression will be determined by multiparameter flow cytometry (MFC) or immunohistochemistry.

• Relapsed or refractory disease, as defined by any of the following:

• Unable to achieve complete response (CR) despite >= 4 weeks of initial course of systemic therapy.

• Recurrence of disease at any point after CR was achieved.

• (Note: patients with Ph-positive disease must have received >= 1 second- or third-generation ABL kinase inhibitor as part of their prior treatment to be eligible.)

• Detectable disease, as defined by any of the following:

• Presence of >= 5% abnormal blasts in the bone marrow or peripheral blood by morphology or MFC.

• Patients with isolated extramedullary disease will be permitted if there is >= 1 site of disease that measures >= 1.5 cm in longest diameter on cross-sectional imaging.

• Absolute neutrophil count (ANC) >= 1,000/uL.

• Hemoglobin >= 8 g/dL.

• Platelets >= 50,000/uL.

• Note: Transfusions and growth factor support will be permitted within 3 days of initiation of study treatment to reach these thresholds. As patients with relapsed/refractory ALL frequently have cytopenias due to marrow infiltration by the disease, no hematologic parameters will be required for enrollment if cytopenias can be attributed to disease.

• Total serum bilirubin =< 1.5 x upper limit of normal (ULN); (unless due to Gilbert syndrome or hemolysis; =< 2 x ULN for hepatic abnormalities considered disease-related).

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN.

• Serum creatinine =< 1.5 x ULN or serum creatinine level associated with a measured or calculated creatinine clearance of >= 40 mL/min.

• Corrected QT (QTc) interval =< 500 msec; if assessed, left ventricular ejection fraction >= 40%.

• An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Must agree to the use of effective contraception while on study treatment, unless they are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] women who are and men whose sexual partner[s] is/are postmenopausal [i.e., a woman who is > 50 years old or who has not had menses for >= 1 year], or [3] not heterosexually active for the duration of the study).

Exclusion Criteria:

• Patients with a circulating blast count of > 50,000/uL; systemic therapy with either hydroxyurea, vincristine, and/or corticosteroids will be permitted within 3 days of initiation of study treatment to reduce the blast count.

• Except for management of circulating blasts noted above, adequate duration from prior therapy must be achieved before initiation of study treatment, as defined below:

• No cytotoxic or targeted systemic therapy < 2 weeks or 5 half-lives (whichever is shorter).

• No blinatumomab < 2 weeks.

• No radiation therapy < 4 weeks.

• No monoclonal antibody therapy < 6 weeks (except for prior InO, as discussed below).

• Patients previously treated with InO will be eligible, unless they meet ANY of the following criteria:

• > 6 individual doses (e.g., > 2 standard cycles) were administered.

• Any documented hepatic toxicity observed was grade 3 or higher.

• The most recent dose was administered < 3 months from the initiation of study treatment.

• For patients that have received prior allogeneic HCT, they must be >= 4 months from the date of stem cell infusion, with no prior history of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), and off all treatment for graft-vs-host disease (GVHD) for >= 2 weeks. Patients with minimal active symptoms that can be controlled with topical therapies and/or the equivalent of prednisone =< 10 mg/day will be eligible.

• For patients that have received other forms of cellular immunotherapy (e.g., chimeric antigen receptor-modified [CAR] T cells), they must be >= 21 days from cell infusion, and any specific manifestations of cytokine release syndrome or neurologic toxicity attributable to the cellular therapy have completely resolved (i.e., < grade 1)

• Patients with a known history of chronic liver disease, including but not limited to cirrhosis, steatohepatitis, and chronic viral hepatitis. Patients with a history of GVHD of the liver will be permitted, provided they meet all of the other eligibility criteria.

• Patients with isolated testicular or central nervous system disease.

• Known hypersensitivity or intolerance to any of the agents under investigation.

• May not be pregnant or nursing.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, Non-Hodgkin
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Recurrence
• Recurrent B Acute Lymphoblastic Leukemia
• Recurrent B Lymphoblastic Lymphoma
• Refractory B Acute Lymphoblastic Leukemia
• Refractory B Lymphoblastic Lymphoma

Intervention

Drug:
• Etoposide
Given IV
• Doxorubicin
Given IV
• Vincristine
Given IV
• Prednisone
Given PO or IV
• Cyclophosphamide
Given IV

Biological:
• Inotuzumab Ozogamicin
Given IV

Locations

Country	Name	City	State
United States	Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
University of Washington	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of inotuzumab ozogamicin (InO)	Will be defined as the highest dose of InO administered in which the incidence of dose limiting toxicities (DLTs) is < 33%, assuming at least 6 patients have been treated at this dose. DLTs assessed by: Non-hematologic toxicities >= grade 3 evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 (except for febrile neutropenia/infection, unless felt to be a direct consequence of treatment-related toxicity [e.g., intestinal infection following mucosal barrier breakdown]).; Any instance of possible, probably, or definite SOS/VOD; Inability to complete 1 full cycle due to treatment-related adverse events; Any treatment delays > 3 weeks (i.e., to Day 50 of Cycle 1) for recovery of prolonged toxicity	Up to 5 years
Secondary	Complete response (CR) rate	Rate of complete response (CR) by bone marrow morphology and/or imaging.	Up to 5 years
Secondary	Rate of complete minimal residual disease (MRD) response	Assessed by multiparameter flow cytometry (MFC).	Up to 5 years
Secondary	Progression-free survival		Up to 5 years
Secondary	Relapse-free survival		Up to 5 years
Secondary	Overall survival		Up to 5 years
Secondary	Rate at which patients proceed to subsequent allogeneic hematopoietic cell transplantation (HCT)		Up to 5 years